These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 34288444)

  • 1. Flow cytometric myeloma measurable residual disease testing in the era of targeted therapies.
    Ng DP
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():71-77. PubMed ID: 34288444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma.
    Broijl A; de Jong ACM; van Duin M; Sonneveld P; Kühnau J; van der Velden VHJ
    Am J Clin Pathol; 2022 Apr; 157(4):494-497. PubMed ID: 34643211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
    Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
    Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of measurable residual disease in multiple myeloma by multiparametric flow cytometry: Current paradigm, guidelines, and future applications.
    Soh KT; Wallace PK
    Int J Lab Hematol; 2021 Jul; 43 Suppl 1():43-53. PubMed ID: 34288449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal Residual Disease Detection by Flow Cytometry in Multiple Myeloma: Why and How?
    Roshal M
    Semin Hematol; 2018 Jan; 55(1):4-12. PubMed ID: 29759152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Artifactual Kappa Light Chain Restriction of Marrow Hematogones: A Potential Diagnostic Pitfall in Minimal Residual Disease Assessment of Plasma Cell Myeloma Patients on Daratumumab.
    Jiang XY; Luider J; Shameli A
    Cytometry B Clin Cytom; 2020 Jan; 98(1):68-74. PubMed ID: 31313879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting.
    Arroz M; Came N; Lin P; Chen W; Yuan C; Lagoo A; Monreal M; de Tute R; Vergilio JA; Rawstron AC; Paiva B
    Cytometry B Clin Cytom; 2016 Jan; 90(1):31-9. PubMed ID: 25619868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
    Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
    Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.
    Soh KT; Tario JD; Wallace PK
    Clin Lab Med; 2017 Dec; 37(4):821-853. PubMed ID: 29128071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition.
    Stetler-Stevenson M; Paiva B; Stoolman L; Lin P; Jorgensen JL; Orfao A; Van Dongen J; Rawstron AC
    Cytometry B Clin Cytom; 2016 Jan; 90(1):26-30. PubMed ID: 25907102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
    Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
    Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction to multiple myeloma special issue: The flow cytometric detection of minimal residual disease.
    Preffer FI; Yuan CM; Lin P; Stetler-Stevenson M; Marti GE
    Cytometry B Clin Cytom; 2016 Jan; 90(1):9-10. PubMed ID: 26780351
    [No Abstract]   [Full Text] [Related]  

  • 14. The evaluation of minimal residual disease in multiple myeloma by fluorescent molecular beacons in real time PCR of IgH gene rearrangements and correlation with flow cytometry.
    Kara IO; Duman BB; Afsar CU
    J BUON; 2013; 18(2):442-7. PubMed ID: 23818359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mature B- and plasma-cell flow cytometric analysis: A review of the impact of targeted therapy.
    Gao Q; Chen X; Cherian S; Roshal M
    Cytometry B Clin Cytom; 2023 May; 104(3):224-242. PubMed ID: 36321879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The Significance of CD319 and CD269 in the Detection of Immunophenotyping and Minimal Residual Disease in Multiple Myeloma Patients].
    Chu B; Wang YT; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Bao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1195-1202. PubMed ID: 34362502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of response to therapy in multiple myeloma by multiparameter flow cytometry. Usefulness of an eight-color single tube with monoclonal antibodies in dried formulation.
    Carulli G; Tarasco A; Sammuri P; Ottaviano V; Domenichini C; Ciancia EM; Petrini M
    Clin Ter; 2019; 170(5):e352-e356. PubMed ID: 31612192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Participation in the College of American Pathologists Laboratory Accreditation Program Decreases Variability in B-Lymphoblastic Leukemia and Plasma Cell Myeloma Flow Cytometric Minimal Residual Disease Testing: A Follow-up Survey.
    Hupp MM; Bashleben C; Cardinali JL; Dorfman DM; Karlon W; Keeney M; Leith C; Long T; Murphy CE; Pillai V; Rosado FN; Seegmiller AC; Linden MA
    Arch Pathol Lab Med; 2021 Mar; 145(3):336-342. PubMed ID: 32886757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Minimal residual disease monitoring by flow cytometry in children with acute lymphoblastic leukemia].
    Popov AM; Verzhbitskaia TIu; Tsaur GA; Shorikov EV; Savel'ev LI; Tsvirenko SV; Fechina LG
    Klin Lab Diagn; 2010 Aug; (8):36-41. PubMed ID: 20886718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma-An evidence-based approach.
    Rai S; Das N; Gupta R; Kumar L; Sharma A; Singh S; Prajapati VK
    Int J Lab Hematol; 2023 Apr; 45(2):179-186. PubMed ID: 36403963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.